[go: up one dir, main page]

PH12015500353A1 - Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations - Google Patents

Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations

Info

Publication number
PH12015500353A1
PH12015500353A1 PH12015500353A PH12015500353A PH12015500353A1 PH 12015500353 A1 PH12015500353 A1 PH 12015500353A1 PH 12015500353 A PH12015500353 A PH 12015500353A PH 12015500353 A PH12015500353 A PH 12015500353A PH 12015500353 A1 PH12015500353 A1 PH 12015500353A1
Authority
PH
Philippines
Prior art keywords
metadoxine
treatment
extended release
release formulations
liver diseases
Prior art date
Application number
PH12015500353A
Inventor
Gulik Van Frederick
Rao Yamsani Madhusudan
Prabha Shankar Bodapunti
Original Assignee
Eurodrug Lab B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurodrug Lab B V filed Critical Eurodrug Lab B V
Publication of PH12015500353A1 publication Critical patent/PH12015500353A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the use of metadoxine in the prevention and in the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), in the improvement of the survival rate of patients with Severe Alcoholic Hepatitis and to a new extended release pharmaceutical formulations comprising metadoxine.
PH12015500353A 2012-09-26 2015-02-18 Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations PH12015500353A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2012004028 2012-09-26
PCT/EP2013/000183 WO2014048511A1 (en) 2012-09-26 2013-01-22 Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations

Publications (1)

Publication Number Publication Date
PH12015500353A1 true PH12015500353A1 (en) 2015-04-20

Family

ID=47018954

Family Applications (2)

Application Number Title Priority Date Filing Date
PH12015500353A PH12015500353A1 (en) 2012-09-26 2015-02-18 Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations
PH12016501553A PH12016501553B1 (en) 2012-09-26 2016-08-05 Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH12016501553A PH12016501553B1 (en) 2012-09-26 2016-08-05 Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations

Country Status (6)

Country Link
KR (1) KR20150063040A (en)
BR (1) BR112015006642B1 (en)
MX (1) MX2015003810A (en)
PE (1) PE20151323A1 (en)
PH (2) PH12015500353A1 (en)
WO (1) WO2014048511A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103976970A (en) * 2014-06-06 2014-08-13 程奉平 Method for preparing metadoxine sustained release tablet

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301108C (en) * 2004-10-15 2007-02-21 山东齐都药业有限公司 Metadoxine dispersible tablet and preparation method thereof
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
KR101697773B1 (en) * 2008-03-10 2017-01-18 유로드러그 레버러토리즈 비. 브이. Modified release composition comprising doxofylline
IT1393338B1 (en) * 2009-03-06 2012-04-20 Baldacci Lab Spa THERAPEUTIC USE OF METADOXINE AS AN INHIBITOR OF THE LIVER FIBROSIS.
NZ597319A (en) * 2009-06-25 2014-06-27 Alcobra Ltd A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
WO2011061743A1 (en) * 2009-11-18 2011-05-26 Alcobra Ltd. Metadoxine and derivatives thereof for use in the treatment of inflammation and immune-related disorders

Also Published As

Publication number Publication date
PH12016501553B1 (en) 2022-03-23
BR112015006642B1 (en) 2022-08-02
KR20150063040A (en) 2015-06-08
MX2015003810A (en) 2015-07-17
WO2014048511A1 (en) 2014-04-03
BR112015006642A2 (en) 2017-07-04
PE20151323A1 (en) 2015-10-10
PH12016501553A1 (en) 2017-09-11

Similar Documents

Publication Publication Date Title
MX360979B (en) Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
IN2014MN00986A (en)
IN2012MN02591A (en)
MX349004B (en) New compounds.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
GB201118656D0 (en) New compounds
IL231536A (en) Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases
IN2015DN00376A (en)
IN2012DN06720A (en)
IN2014MN00988A (en)
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12014500386A1 (en) Combination treatment for hepatitis c
PH12013501915A1 (en) Intranasal benzodiazepine pharmaceutical compositions
MX2019005082A (en) Compositions comprising 15-ohepa and methods of using the same.
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
MX2015005111A (en) Herbal composition for the prevention and treatment of tnf-î± mediated diseases.
IN2014DN09240A (en)
PH12016501553A1 (en) Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations
PH12015500070B1 (en) Pediatric oral liquid compositions containing nepadutant
ES2446494B1 (en) Therapeutic application of necrostatin-1 in steatohepatitis
NZ707033A (en) Dispersible nimorazole tablet
MY159675A (en) Clerodane derivatives for modulation of leukotriene receptor activity and related diseases
UA64822U (en) method for medical rehabilitation of patients with non-alcoholic steatohepatitis
UA64821U (en) method for medical rehabilitation of patients with chronic uncalculary cholecystitis combined with obesity